Market Capitalization (Millions $) |
39 |
Shares
Outstanding (Millions) |
29 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
9 |
Cash Flow (TTM) (Millions $) |
-1 |
Capital Exp. (TTM) (Millions $) |
0 |
Entera Bio Ltd
Entera Bio Ltd is a biotechnology company that specializes in oral delivery of large molecule drugs and biologics. They develop and commercialize oral formulations of drugs typically administered by injection, with the aim of improving patient outcomes and convenience. The company utilizes a proprietary oral protein delivery platform to develop these formulations. Their technology involves encapsulating the drugs in a protective delivery vehicle, allowing them to survive the harsh conditions of the gastrointestinal tract and be effectively absorbed into the bloodstream. Entera Bio is focused on developing therapies for various diseases, including osteoporosis, hypoparathyroidism, and inflammatory bowel disease. Their mission is to revolutionize drug delivery by enabling patients to take important medications orally, thus eliminating the need for injections.
Company Address: Kiryat Hadassah Jerusalem 9112002
Company Phone Number: 2-532-7151 Stock Exchange / Ticker: NASDAQ ENTX
ENTX is expected to report next financial results on March 30, 2024. |
|
|